Social confidence, social inclusion, social networks, or personalised quality of life ‐ not reported · patients with antipsychotic‐induced tardive dyskinesia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Global state: No clinically significant response (as defined by the original studies) · patients with schizophrenia
Quetiapine showed no clear difference in global state No clinical significant response as defined by the… compared with typical antipsychotics (moderate certainty).
1 finding from 1 review
Leaving the study early · patients with schizophrenia
Quetiapine showed no clear difference in leaving the study early due to any reason compared with typical antipsychotics (moderate certainty).
1 finding from 1 review
Mental state: 2. Positive symptoms ‐ average endpoint score PANSS positive subscore · patients with schizophrenia
1 finding from 1 review
Mental state: 3. Negative symptoms ‐ average endpoint score PANSS negative subscore · patients with schizophrenia
1 finding from 1 review
Cognitive function · patients with schizophrenia
1 finding from 1 review
Adverse effects: unspecified extrapyramidal symptoms · patients with schizophrenia
Quetiapine probably leads to lower extrapyramidal effects compared with typical antipsychotics (moderate certainty).
1 finding from 1 review
Prolactin level Average level in ng/mL · patients with schizophrenia
1 finding from 1 review
Relapse · patients with schizophrenia
CLOZAPINE probably leads to lower relapse ‐ short term compared with TYPICAL ANTIPSYCHOTICS ‐ OVERALL (moderate certainty).
4 findings from 1 review
RR 0.62 [0.45, 0.84]
19 studies · 1303 participants
Moderate
RR 0.22 [0.14, 0.34]
4 studies · 578 participants
Moderate
RR 1.04 [0.61, 1.78]
4 studies · 396 participants
Moderate
Show 1 more finding
Global state: no improvement ‐ medium termAs defined in each study · patients with schizophrenia
CLOZAPINE probably leads to lower global impression: 1. Not clinically improved ‐ short term compared with TYPICAL ANTIPSYCHOTICS (moderate certainty).
3 findings from 1 review
RR 0.71 [0.64, 0.79]
4 studies · 370 participants
Moderate
RR 0.83 [0.76, 0.91]
2 studies · 648 participants
Moderate
RR 0.72 [0.66, 0.79]
14 studies · 1119 participants
Moderate
Adverse effects 1. Blood problems · patients with schizophrenia
CLOZAPINE showed no clear difference in adverse effects 1. Blood problems compared with TYPICAL ANTIPSYCHOTICS; GRADE not reported.
1 finding from 1 review
Adverse effects 4. Salivation ‐ too much · patients with schizophrenia
CLOZAPINE probably leads to higher adverse effects 4. Salivation ‐ too much compared with TYPICAL ANTIPSYCHOTICS (moderate certainty).
2 findings from 1 review
Weight gain · patients with schizophrenia
CLOZAPINE probably leads to higher adverse effects 5. Weight gain compared with TYPICAL ANTIPSYCHOTICS (moderate certainty).
2 findings from 1 review
Unable to work · patients with schizophrenia
CLOZAPINE showed no clear difference in unable to work compared with TYPICAL ANTIPSYCHOTICS ‐ OVERALL (moderate certainty).
1 finding from 1 review
Adverse effects: 1. Blood problems ‐ decreased white cell count · patients with schizophrenia
CLOZAPINE probably leads to higher adverse effects: 1. Blood problems ‐ decreased white cell count compared with TYPICAL ANTIPSYCHOTICS ‐ OVERALL (moderate certainty).
1 finding from 1 review